Abstract:HepatoBiliary Surg Nutr 2021 | https://dx.doi.org/10.21037/hbsn-21-365 Colorectal liver metastases (CRLM) are one of the most frequent clinical conditions. Over the last 20 years, the clinical outcome for patients with CRLM has improved greatly. Liver resection is the gold standard treatment for resectable CRLM, achieving a 5-year overall survival (OS) rate of 42% (1). However, the majority of patients with CRLM are not candidates for resection. With the development of thermal ablation, this technique provides an alternative treatment modality by either ablation alone or combined with resection. A recent review by Takahashi et al. summarized the current role of thermal ablation in the management of CRLM (2). In this review, the authors stated that ablation should not be used in lieu of liver resection for resectable CRLM based on current available evidence. Regarding the rapid advancement of systemic and local therapy, the treatment strategies for patients with CRLM are suggested to be discussed by the multidisciplinary team (MDT). Also, the authors listed the indications of ablation in their center, including unresectable liver lesions (tumor number ≤8, tumor size ≤4 cm), combined with hepatectomy, and resectable liver lesions but patients unfit to receive resection because of comorbidities and patient preference. These indications are highly feasible and can be referred by readers. It is noteworthy that the preferred tumor size and number were inconsistent in the light of the clinician’s experience. In general, thermal ablation is recommended for tumor size ≤3 cm. For tumor size between 3 and 5 cm, welllocated tumors can also be effectively treated depending on anatomical position and the treatment protocol used (3). Tumor number varies from 5 to 9 in the literature, which depends on the total liver tumor volume. The authors then pointed out the pros and cons of 3 approaches to perform ablation. Open and laparoscopy approaches allow better staging for occult liver metastases or peritoneal disease and protect surrounding organs from thermal injuries. It has been reported that additional metastases were detected in 10–25% of patients with CRLM by intraoperative ultrasound (4), which may result in changing the surgical strategy. The percutaneous approach provides the least invasive approach and has a significant role in patients with limited recurrent liver metastases after resection or ablation. Moreover, percutaneous ablation can be used as the ‘test-of-time’ approach reported by Livraghi et al. (5). The rationale of this approach is: (I) high technical success rate of ablation for small tumors without the need for resection; (II) if ablation was unsuccessful, the resection was still feasible; (III) if patients develop additional lesions after ablation and would no longer be suitable for resection, they can be spared unnecessary surgery. Among the 88 patients treated in the study by Livraghi et al. (5), 26% remained free of disease without the need for resection, 24% underwent resection after ablation, and 50% were unfit for resection due to disease progression. Compared with liver resection, local tumor recurrence (LTR) is a major issue after ablation. Predictors of LTR include tumor size ≥3 cm and ablation margin ≤0.5 cm. In Editorial

Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma

Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation

Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017

Outcomes and Complications of Image-Guided Percutaneous Tumour Ablation for Hepatocellular Carcinoma at the Irish National Liver Transplant Centre

Correlation of Needle Biopsy-Acquired Histopathologic Grade of Hepatocellular Carcinoma with Outcomes after Thermal Ablation

MR-guided laser thermal ablation of primary and secondary liver tumours

Evaluation of the Contrast-Enhanced Ultrasound Nonradiation Treatment Response Assessment LI-RADS v2024 Using Data From a Multi-Center Transarterial Chemoembolization Study

Laparoscopic Ultrasound Graded Radiofrequency Ablation for Hepatocellular Carcinoma:Preliminary Experience

Thermal ablation versus liver resection for hepatocellular carcinoma in patients with cirrhosis: a systematic review and meta-analysis of propensity-score matched studies

Treatment Efficacy of Radiofrequency Ablation of 338 Patients with Hepatic Malignant Tumor and the Relevant Complications.

Clinical Short—term Results of Radiofrequency Ablation in L;iver Cancers

[Efficacy of Radiofrequency Ablation of 343 Patients with Hepatic Tumor and the Relevant Complications].

[The Importance of Image Guided Radiofrequency Ablation with Standard Treatment Strategy for Liver Malignancies].

The Current Application of Thermal Ablation in Colorectal Liver Metastasis.

Combined transarterial chemoembolization and thermal ablation in candidates to liver transplantation with hepatocellular carcinoma: pathological findings and post-transplant outcome

Liver Resection versus Radiofrequency Ablation plus Transcatheter Arterial Chemoembolization in Cirrhotic Patients with Solitary Large Hepatocellular Carcinoma

LI-RADS radiation-based treatment response algorithm for HCC: what to know and how to use it

Local Ablation Therapy for Hepatocellular Carcinoma: Clinical Significance of Tumor Size, Location, and Biology

Efficacy and Safety of Local Liver Radioablation in Hepatocellular Carcinoma Lesions within and beyond Limits of Thermal Ablation

Longitudinal assessment of hepatocellular carcinoma response to stereotactic body radiation using gadoxetate-enhanced MRI: A case series

Intraprocedural assessment of ablation margins using computed tomography co-registration in hepatocellular carcinoma treatment with percutaneous ablation: IAMCOMPLETE study